SG11201806688QA - Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses - Google Patents
Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and usesInfo
- Publication number
- SG11201806688QA SG11201806688QA SG11201806688QA SG11201806688QA SG11201806688QA SG 11201806688Q A SG11201806688Q A SG 11201806688QA SG 11201806688Q A SG11201806688Q A SG 11201806688QA SG 11201806688Q A SG11201806688Q A SG 11201806688QA SG 11201806688Q A SG11201806688Q A SG 11201806688QA
- Authority
- SG
- Singapore
- Prior art keywords
- trifluoroacetate salt
- crystalline form
- tlr7 agonist
- preparation methods
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610081899.3A CN107043377A (zh) | 2016-02-05 | 2016-02-05 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
| PCT/CN2017/072894 WO2017133687A1 (zh) | 2016-02-05 | 2017-02-04 | 一种tlr7激动剂的三氟乙酸盐、晶型b、制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806688QA true SG11201806688QA (en) | 2018-09-27 |
Family
ID=59500539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806688QA SG11201806688QA (en) | 2016-02-05 | 2017-02-04 | Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10683296B2 (zh) |
| EP (1) | EP3412674B1 (zh) |
| JP (1) | JP6877450B2 (zh) |
| KR (1) | KR102393281B1 (zh) |
| CN (2) | CN107043377A (zh) |
| AR (1) | AR107550A1 (zh) |
| AU (1) | AU2017214135B2 (zh) |
| BR (1) | BR112018015878A2 (zh) |
| CA (1) | CA3013521C (zh) |
| CL (1) | CL2018002101A1 (zh) |
| DK (1) | DK3412674T3 (zh) |
| EA (1) | EA037048B1 (zh) |
| ES (1) | ES2834304T3 (zh) |
| HK (1) | HK1259182A1 (zh) |
| HU (1) | HUE052210T2 (zh) |
| IL (1) | IL260981B (zh) |
| MX (1) | MX2018009503A (zh) |
| NZ (1) | NZ745023A (zh) |
| PH (1) | PH12018501641A1 (zh) |
| SG (1) | SG11201806688QA (zh) |
| TW (1) | TWI778952B (zh) |
| UA (1) | UA121276C2 (zh) |
| WO (1) | WO2017133687A1 (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| KR20210013183A (ko) * | 2018-05-25 | 2021-02-03 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | Tlr7 작용제 및 폐암을 치료하기 위한 이의 약학 조합물 |
| MX2021009496A (es) | 2019-02-08 | 2021-09-08 | Progeneer Inc | Complejo de colesterol-agonista del receptor 7 u 8 tipo larga distancia, y uso del mismo. |
| CN115666637A (zh) | 2020-03-02 | 2023-01-31 | 蛋白科技先锋 | 基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法 |
| US20230355750A1 (en) | 2020-08-04 | 2023-11-09 | Progeneer Inc. | Kinetically acting adjuvant ensemble |
| JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途 |
| US20230346924A1 (en) | 2020-08-04 | 2023-11-02 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
| TW202334164A (zh) | 2022-01-12 | 2023-09-01 | 美商戴納立製藥公司 | （Ｓ）－５－苄基－Ｎ－（５－甲基－４－側氧基－２，３，４，５－四氫吡啶並［３，２－ｂ］［１，４］氧氮呯－３－基）－４Ｈ－１，２，４－三唑－３－甲醯胺的晶型 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3376479B2 (ja) * | 1991-08-12 | 2003-02-10 | 武田薬品工業株式会社 | 縮合ピリミジン誘導体、その製造法および用途 |
| AU2009333559B2 (en) | 2008-12-09 | 2015-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| JP5813785B2 (ja) * | 2011-02-04 | 2015-11-17 | デュケイン ユニバーシティー オブ ザ ホリー スピリット | 抗チューブリン活性を有する二環式および三環式のピリミジンチロシンキナーゼ阻害剤ならびに患者の処置方法 |
| EP2800569B1 (en) * | 2012-01-05 | 2018-07-25 | Northeastern University | Allosteric modulators of cb1 cannabinoid receptors |
| JP6293765B2 (ja) * | 2012-10-10 | 2018-03-14 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染症および他の疾患の処置のためのピロロ［３，２−ｄ］ピリミジン誘導体 |
| WO2014081644A1 (en) * | 2012-11-20 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds |
| WO2015168269A1 (en) * | 2014-05-01 | 2015-11-05 | Novartis Ag | Compounds and compositions as toll-like receptor 7 agonists |
| SG11201608299TA (en) * | 2014-05-01 | 2016-11-29 | Novartis Ag | Compounds and compositions as toll-like receptor 7 agonists |
| SG11201701169XA (en) * | 2014-08-15 | 2017-03-30 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Pyrrolopyrimidine compounds used as tlr7 agonist |
| CN105367576A (zh) * | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| CN105732635A (zh) | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
-
2016
- 2016-02-05 CN CN201610081899.3A patent/CN107043377A/zh active Pending
-
2017
- 2017-02-03 TW TW106103697A patent/TWI778952B/zh active
- 2017-02-04 SG SG11201806688QA patent/SG11201806688QA/en unknown
- 2017-02-04 WO PCT/CN2017/072894 patent/WO2017133687A1/zh active Application Filing
- 2017-02-04 NZ NZ745023A patent/NZ745023A/en unknown
- 2017-02-04 EA EA201891772A patent/EA037048B1/ru not_active IP Right Cessation
- 2017-02-04 DK DK17747007.7T patent/DK3412674T3/da active
- 2017-02-04 KR KR1020187024629A patent/KR102393281B1/ko active IP Right Grant
- 2017-02-04 UA UAA201809128A patent/UA121276C2/uk unknown
- 2017-02-04 CA CA3013521A patent/CA3013521C/en active Active
- 2017-02-04 JP JP2018540797A patent/JP6877450B2/ja active Active
- 2017-02-04 US US16/075,303 patent/US10683296B2/en active Active
- 2017-02-04 AU AU2017214135A patent/AU2017214135B2/en active Active
- 2017-02-04 ES ES17747007T patent/ES2834304T3/es active Active
- 2017-02-04 EP EP17747007.7A patent/EP3412674B1/en active Active
- 2017-02-04 MX MX2018009503A patent/MX2018009503A/es active IP Right Grant
- 2017-02-04 CN CN201780009751.1A patent/CN108602833B/zh active Active
- 2017-02-04 HU HUE17747007A patent/HUE052210T2/hu unknown
- 2017-02-04 BR BR112018015878-0A patent/BR112018015878A2/zh active Search and Examination
- 2017-02-06 AR ARP170100299A patent/AR107550A1/es unknown
-
2018
- 2018-08-02 PH PH12018501641A patent/PH12018501641A1/en unknown
- 2018-08-03 CL CL2018002101A patent/CL2018002101A1/es unknown
- 2018-08-05 IL IL260981A patent/IL260981B/en unknown
-
2019
- 2019-01-24 HK HK19101232.5A patent/HK1259182A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501641A1 (en) | Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses | |
| PH12018501643A1 (en) | Tlr7 agonist crystalline form a, preparation method and use thereof | |
| PH12019500930A1 (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| NZ747259A (en) | Soluble c5ar antagonists | |
| PH12017500281A1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
| PH12018501644A1 (en) | Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms | |
| MX2017001284A (es) | Tieno [3,2-d] pirimidina, furo[3,2-d] pirimidina y pirrolo [3,2-d] pirimidinas utiles para el tratamiento de infecciones por virus sincitial respiratorio. | |
| MX2018009502A (es) | Metodo para preparar compuesto de pirrolo[3,2-d]pirimidina y sus intermediarios. | |
| MY183123A (en) | Synthesis of copanlisib and its di hydrochloride salt | |
| MX2016003958A (es) | Formas solidas de ceftolozano. | |
| WO2015068175A3 (en) | An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof | |
| PH12018502246A1 (en) | Substituted fused pyrimidinone compounds | |
| WO2016079757A3 (en) | NOVEL PROCESSES FOR THE PREPARATION OF SUBSTITUTED 5-HYDROXYMETHYL-OXAZOLIDINE-2-ONE | |
| WO2015102017A8 (en) | Processes for the preparation of lorcaserin | |
| MY197130A (en) | Tlr7 agonist crystalline form a, preparation method and use thereof | |
| CO2017002070A2 (es) | Un proceso para la preparación de derivados de 3-fenil/heteroaril-6-fenoxi-8-alquilamino-imidazo[1,2-b] piridazina | |
| GB2527958A (en) | Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents |